Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Prashanth Ashok KumarMulham OmbadaGayatri PemmasaniAjay TambeKatalin BankiTeresa GentilePublished in: Journal of investigative medicine high impact case reports (2022)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed and recurrent setting. We present a case of refractory BPDCN in a 62-year-old man who showed a complete bone marrow response to liposomal daunorubicin and cytarabine (vyxeos).
Keyphrases
- dendritic cells
- acute myeloid leukemia
- bone marrow
- low grade
- high dose
- regulatory t cells
- immune response
- mesenchymal stem cells
- acute lymphoblastic leukemia
- diffuse large b cell lymphoma
- high grade
- multiple myeloma
- human health
- hodgkin lymphoma
- nk cells
- risk assessment
- type diabetes
- insulin resistance
- skeletal muscle
- weight loss